Z-D-Val-Lys(Z)-OH
Brand names,
Z-D-Val-Lys(Z)-OH
Analogs
Z-D-Val-Lys(Z)-OH
Brand Names Mixture
Z-D-Val-Lys(Z)-OH
Chemical_Formula
C46H56N4O10
Z-D-Val-Lys(Z)-OH
RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
Z-D-Val-Lys(Z)-OH
fda sheet
Z-D-Val-Lys(Z)-OH
msds (material safety sheet)
Z-D-Val-Lys(Z)-OH
Synthesis Reference
No information avaliable
Z-D-Val-Lys(Z)-OH
Molecular Weight
824.958 g/mol
Z-D-Val-Lys(Z)-OH
Melting Point
220 oC
Z-D-Val-Lys(Z)-OH
H2O Solubility
No information avaliable
Z-D-Val-Lys(Z)-OH
State
Solid
Z-D-Val-Lys(Z)-OH
LogP
4.918
Z-D-Val-Lys(Z)-OH
Dosage Forms
Liquid; Solution
Z-D-Val-Lys(Z)-OH
Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
Z-D-Val-Lys(Z)-OH
Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Z-D-Val-Lys(Z)-OH
Absorption
No information avaliable
Z-D-Val-Lys(Z)-OH
side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
Z-D-Val-Lys(Z)-OH
Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Z-D-Val-Lys(Z)-OH
Organisms Affected
Humans and other mammals